RICCIARDI, SILVIA
 Distribuzione geografica
Continente #
EU - Europa 209
NA - Nord America 189
AS - Asia 56
SA - Sud America 3
AF - Africa 2
Totale 459
Nazione #
US - Stati Uniti d'America 182
IT - Italia 64
CN - Cina 26
FR - Francia 23
IE - Irlanda 22
GB - Regno Unito 19
IN - India 15
NL - Olanda 14
SE - Svezia 14
DE - Germania 10
SG - Singapore 10
GR - Grecia 7
BA - Bosnia-Erzegovina 6
CA - Canada 4
PL - Polonia 4
RS - Serbia 4
SI - Slovenia 4
ES - Italia 3
HR - Croazia 3
MX - Messico 3
AT - Austria 2
BR - Brasile 2
CH - Svizzera 2
DK - Danimarca 2
KR - Corea 2
ME - Montenegro 2
NG - Nigeria 2
UA - Ucraina 2
AM - Armenia 1
AR - Argentina 1
HU - Ungheria 1
IL - Israele 1
JP - Giappone 1
RO - Romania 1
Totale 459
Città #
Chandler 46
Dublin 22
Milan 14
Amsterdam 12
Nyköping 11
Rome 7
Banja Luka 6
London 6
Paris 6
Preveza 6
Singapore 6
Ashburn 5
Chaponost 5
Medford 5
Mumbai 5
Princeton 5
Turin 5
Belgrade 4
Brookline 4
Fairfield 4
Hangzhou 4
Jacksonville 4
Newcastle upon Tyne 4
Torino 4
Beijing 3
Chengdu 3
Chennai 3
Coyoacán 3
Genay 3
Hyderabad 3
Toulouse 3
Vancouver 3
Zagreb 3
Abuja 2
Andover 2
Atlanta 2
Bengaluru 2
Birmingham 2
Boston 2
Cambridge 2
Celje 2
Dearborn 2
Dossobuono 2
Flanders 2
Fuzhou 2
Genoa 2
Hebei 2
Houston 2
Lake Villa 2
Lenart v Slov. Goricah 2
Madrid 2
Messina 2
Mutterstadt 2
New Delhi 2
New York 2
Nuremberg 2
Padova 2
Philadelphia 2
Phoenixville 2
Pomezia 2
San Francisco 2
Seoul 2
Sevenoaks 2
Shenzhen 2
Stockholm 2
Tarbes 2
Vejle 2
Westfield 2
Woodstock 2
Ann Arbor 1
Brooklyn 1
Budapest 1
Calgary 1
Cardito 1
Cluj-Napoca 1
Coventry 1
Ferrara 1
Frattamaggiore 1
Fremont 1
Geneva 1
Guiyang 1
Gunzenhausen 1
Hellikon 1
Hopkins 1
Kettering 1
Krakow 1
Kunming 1
Lancaster 1
Mannheim 1
Milanówek 1
Monmouth Junction 1
Nanjing 1
Norwalk 1
Parma 1
Petah Tikva 1
Quanzhou 1
Quartu Sant'elena 1
Redwood City 1
Rescaldina 1
Rotterdam 1
Totale 330
Nome #
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 260
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial 73
Expected and paradoxical effects of obesity on cancer treatment response 53
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 47
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 35
Totale 468
Categoria #
all - tutte 1.441
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.441


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202023 0 1 1 2 3 3 6 2 1 1 3 0
2020/202126 0 1 0 0 1 0 1 1 12 4 3 3
2021/202258 3 1 2 1 4 4 5 3 2 4 19 10
2022/2023223 22 19 5 14 13 34 20 21 33 16 14 12
2023/2024134 13 32 15 9 11 15 7 12 1 11 4 4
2024/20254 1 3 0 0 0 0 0 0 0 0 0 0
Totale 468